Contemporary Conversations in Retinopathy of Prematurity

ICROP Classification and ROP Treatment Guidelines

Faruk Orge, MD; and Darius Moshfeghi, MD

Show Description +

Which classification systems exist for retinopathy of prematurity, and how do those classifications inform patient assessment? Faruk Orge, MD, and Darius Moshfeghi, MD, review the evolution of the ICROP classifications for retinopathy of prematurity, which serve as a foundational reference for the ophthalmology community to evaluate findings using a common nomenclature.

Posted: 12/16/2024

Keywords:

Retina

•

ROP

•

Retinopathy of prematurity, ROP,

•

aflibercept

•

Regeneron Pharmaceuticals

•

ICROP

Up Next

Name: ICROP Classification and ROP Treatment Guidelines
Uploaded: 2024-12-16T20:20:26+00:00
Description: Which classification systems exist for retinopathy of prematurity, and how do those classifications inform patient assessment? Faruk Orge, MD, and Darius Moshfeghi, MD, review the evolution of the ICROP classifications for retinopathy of prematurity, which serve as a foundational reference for the ophthalmology community to evaluate findings using a common nomenclature.

Additional Considerations for Treating ROP

Faruk Orge, MD; Darius Moshfeghi, MD

Decision Factors in managing patients with ROP

Faruk Orge, MD; and Darius Moshfeghi, MD

Back to All Videos

ICROP Classification and ROP Treatment Guidelines

Faruk Orge, MD; and Darius Moshfeghi, MD

Which classification systems exist for retinopathy of prematurity, and how do those classifications inform patient assessment? Faruk Orge, MD, and Darius Moshfeghi, MD, review the evolution of the ICROP classifications for retinopathy of prematurity, which serve as a foundational reference for the ophthalmology community to evaluate findings using a common nomenclature.

Posted: 12/16/2024

Keywords:

Retina

•

ROP

•

Retinopathy of prematurity, ROP,

•

aflibercept

•

Regeneron Pharmaceuticals

•

ICROP

About Regeneron

Regeneron is a leading biotechnology company that invents, develops, and commercializes life-transforming medicines for people with serious diseases. Founded and led for nearly 35 years by physician-scientists, Regeneron's unique ability to repeatedly and consistently translate science into medicine has led to numerous FDA-approved treatments and product candidates in development, almost all of which were homegrown in Regeneron's laboratories.

Visit us online: regeneron.com

Follow Regeneron